News

Bemcentinib, formerly known as BGB324, is a potentially first-in-class selective AXL inhibitor.

The partnership will enable Vifor to identify new targets for renal therapies to bolster the company’s pipeline.

Despite the legislation of cannabis being passed a year ago, it remains out of reach for the vast majority of patients.

The drug has been approved and marketed in Europe as Ziextenzo since 2018.

The initiative provides support in developing systems to improve health and social care evidence-based decision making.

The new platform is called ActNow, and people “get back to the comfort of their own home quicker.”

The Global R&D Centre will carry out R&D for potential new innovative medicines, and more than double AstraZeneca’s Shanghai R&D headcount to around 1,000.

The technology is the first-of-its-kind, detecting DNA and protein changes simultaneously.

Antimicrobial resistance could cause as many as 10 million deaths per year by 2050.

the British Heart Foundation has announced the launch a new £1million Hope for Hearts Fund, to test innovative ways of caring for people with heart failure.

Identifying new treatments for liver scarring is “critical” to tackling the epidemic of liver disease.

The proposed improvement could cut costs and save patients avoidable trips to their GP.

The UK CBD market is worth £300m currently, and its double-digit growth each year has led to market value expectations of almost £1bn by 2025.

The projects are part of the NIHR Research and Innovation for Global Health Transformation (RIGHT) programme.